Daraxonrasib Extends Pancreatic Cancer Survival, Targeting KRAS in a First Major Trial Breakthrough
Updated
Updated · The New York Times · May 12
Daraxonrasib Extends Pancreatic Cancer Survival, Targeting KRAS in a First Major Trial Breakthrough
7 articles · Updated · The New York Times · May 12
Daraxonrasib substantially extended the lives of pancreatic cancer patients in a clinical trial, the first drug to show that level of survival benefit in the disease.
KRAS — a protein that drives nearly all pancreatic tumors and many lung and colon cancers — is the drug’s target, overcoming a challenge many researchers had long considered untreatable.
The result follows decades of failed pancreatic cancer drug trials and repeated reversals of scientific dogma about how the smooth-surfaced KRAS protein could be attacked.
With the drug nearing regulatory approval, some scientists say the KRAS-targeting approach could become the biggest cancer-treatment advance in 15 years, since immunotherapy.
Now that the 'undruggable' KRAS protein is conquered, which other 'impossible' diseases are next?
This drug doubles survival, but for how long until cancer learns to resist it?
With a breakthrough drug for pancreatic cancer announced, will its price put it out of reach for most patients?
Daraxonrasib Delivers Unprecedented Survival Gains in Metastatic Pancreatic Cancer: RASolute 302 Phase III Data and the Future of RAS(ON) Targeted Therapy
Overview
Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent inhibitor that marks a significant advancement in pancreatic cancer treatment. As pancreatic cancer is now seen as a genetically driven disease, targeted therapies like daraxonrasib are creating new hope. The upcoming presentation of the full RASolute 302 trial results at the 2026 ASCO Annual Meeting is a pivotal moment, as these findings are highly anticipated and could redefine care for patients. This progress highlights how molecular therapy is becoming an actionable concept, signaling an exciting era in pancreatic cancer care.